FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents

Lymphokine

Lymphokine patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

Related Categories:

Drug, Bio-affecting And Body Treating Compositions


Lymphokine



Use of g-csf dimer in the treatment of neutropenia
05/28/15 - 20150147290 - This invention relates to a use of G-CSF dimer in the treatment of neutropenia. In particular, the recombinant human G-CSF of the present invention can enhance the differentiation and development of neutrophils in animal, and thus effectively reduce the severity of the severe neutropenia and shorten the time of severe...

Zinc chelating agents for depleting xiap and sensitizing tumor cells to apoptosis
05/28/15 - 20150147291 - The invention provides zinc chelating agents and formulations thereof that deplete XIAP in cancer cells and sensitize the cells to apoptosis-inducing agents. The invention provides methods for sensitizing apoptosis-resistant cancer cells to apoptosis-inducing agents, as well as methods for treating a subject with a combined therapy of a zinc chelating...

Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics
05/21/15 - 20150139936 - Provided are methods and compositions for clinical treatment of advanced HER2 positive solid tumors cancer using combination therapies comprising bispecific anti-ErbB2/anti-ErbB3 antibodies....

Methods and compositions for inhibiting diseases of the central nervous system
05/21/15 - 20150139937 - Methods and compositions for treating central nervous system diseases and disorders are disclosed....

Methods and compositions for improving pial collateral circulation and treating blood clotting disorders
05/21/15 - 20150139938 - The present invention provides methods of promoting arteriogenesis in a subject. Embodiments include methods comprising: administering an effective dose of tocotrienol to the subject; causing an increase in Tissue Inhibitor of Metalloproteinase Metallopeptidase Inhibitor 1 (TIMP1) in vessels of cerebrovascular collateral circulation in the subject; attenuating the activity of Matrix...

Trail single chain molecules
05/07/15 - 20150125419 - The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications....

Liquid formulation of g-csf
05/07/15 - 20150125420 - Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits....

Concurrent chemotherapy and immunotherapy
04/30/15 - 20150118181 - The concurrent administration of chemotherapy and immunotherapy has been considered a contraindication because of the concern that the induced lymphopenia would ablate therapeutic efficacy of immunotherapy. Temozolomide has been shown to be an effective chemotherapeutic for patients with malignant gliomas and to deprive patients with glioblastoma (GBM) patients of this...

Novel antitumoral use of cabazitaxel
04/30/15 - 20150118182 - which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment....

Trail single chain molecules
04/23/15 - 20150110734 - The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications....

Human monoclonal antibodies to ctla-4
04/16/15 - 20150104409 - In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within...

Serpin fusion polypeptides and methods of use thereof
04/16/15 - 20150104410 - This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an...

Novel antitumoral use of cabazitaxel
04/16/15 - 20150104411 - which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment....

Materials and methods useful for affecting tumor cell growth, migration and invasion
04/16/15 - 20150104412 - It is disclosed herein that miR-221 and miR-222 down-regulate PTEN and TIMP3 tumor suppressors, resulting in TRAIL resistance. The present invention provides research, diagnostic, and therapeutic tools and methods related to this discovery. Diagnostics, prognostics and treatments for human hepatocellular cancer and non-small cell lung carcinoma having a TRAIL resistance...

Method for ex-vivo purging in autologous transplantation
04/09/15 - 20150098924 - The present invention concerns a new method for ex-vivo purging of cells in autologous transplantation, wherein the sample of taken cells is treated with a sufficient amount of a multimeric form of the soluble portion of FasL to kill malignant cells without substantially affecting viability of cells to be transplanted....

Use of amg 900 for the treatment of cancer
03/19/15 - 20150079022 - The present invention relates to methods of using AMG 900, a small molecule pan aurora kinase inhibitor, for the treatment of cancer, including solid tumors, hematologically derived tumors and the like. The invention further provides pharmaceutical compositions, dosage ranges and treatment regimens for administering AMG 900 to treat cancer....

Cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
03/12/15 - 20150071873 - A first and a second identical or different mycobacterial immunogenic compositions, each comprising at least a Mycobacterium bovis bacillus Calmette-Guerin (BCG), an antigenically related non-pathogenic mycobacteria, or one or more immunogenic component(s) thereof, as therapeutic active ingredient(s) for use in the treatment of cancer by parenteral or oral administration of...

Treatment methods for rheumatoid arthritis
03/05/15 - 20150064132 - The present invention provides methods for selecting treatment methods for rheumatoid arthritis based on an objective selection process (algorithm). The present invention also provides methods for treating rheumatoid arthritis with treatment methods selected based on the algorithm disclosed herein. The methods of the present invention provide a more effective means...

The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
02/26/15 - 20150056159 - The present invention provides a polypeptides comprising a heavy chain domain 2 (HD2) from IgM or IgE and at least one pharmaceutically active moiety, complexes thereof and their use for therapy and prophylaxis....

Anticancer fusion protein
02/12/15 - 20150044162 - A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity, preferably 85% identity and ending with the amino...

A method for cuticle growth using granulocyte-colony stimulating factor
02/12/15 - 20150044163 - The present invention provides a method for re-growing hair in patients with androgenic alopecia by administering effective consecutive courses of Granulocyte-Colony Stimulating Factor or derivatives. After the state of re-growth is obtained, the hair growth is maintained by administering periodic courses of Granulocyte-Colony Stimulating Factor or derivatives. The invention further...

Use of cxcr4 antagonists
01/29/15 - 20150030561 - Presently disclosed are methods and compositions for treating or preventing WHIM syndrome and certain other disorders or conditions with a certain CXCR4 antagonist....

Reactivation of hiv-1 gene expression to treat persistent hiv infection
01/22/15 - 20150023907 - The present invention provides new methods of treatment of lentiviral infections, more particularly to treat latent retroviral HIV infections, present in cells of the infected subject, based on the re-activation of said viruses. The invention uses a combination therapy using several agents that result in strong re-activation of the latent...

Methods for diagnosis, prognosis and methods of treatment
01/15/15 - 20150017119 - The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that...

Polysaccharide-protein conjugates reversibly coupled via imine bonds
01/08/15 - 20150010494 - A method of preparing an oxidised polysaccharide-protein conjugate by oxidising a polysaccharide with an oxidising agent to form an oxidised polysaccharide and combining such oxidised polysaccharide with a protein. The oxidised polysaccharide is reacted with a protein to form a composition comprising a conjugate wherein the oxidised polysaccharide and the...

Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins
01/01/15 - 20150004129 - The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. The oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a...

Nutritional composition for improving the mammalian immune system
01/01/15 - 20150004130 - for improving the immune function in a mammal, preferably a human....

Materials and methods to enhance hematopoietic stem cells engraftment procedures
12/25/14 - 20140377214 - This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE2 biosynthesis or PGE2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF,...

Delivery of therapeutic agents by a collagen binding protein
12/25/14 - 20140377215 - Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF)...

Anticancer fusion protein
12/25/14 - 20140377216 - A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity, preferably 85% identity and ending with the amino...

Mirna biomarkers for radiation biodosimetry
11/20/14 - 20140341841 - Disclosed herein are miRNA biomarkers and methods for measuring exposure of a mammalian subject to ionizing radiation using a cell-free biological sample. Also disclosed are dosimeters and methods for triaging and treating a subject exposed to ionizing radiation....

Thiolated hyaluronan-based hydrogels cross-linked using oxidized glutathione
11/20/14 - 20140341842 - The invention provides methods, compositions and kits relating to hyaluronan based matrices using oxidized glutathione as a crosslinking agent....

Compositions, methods and systems for regenerative cosmetics
11/13/14 - 20140335046 - A method of inducing or promoting hair growth on the scalp of a subject, comprising the steps of (i) providing an ECM composition including at least one ECM material, (ii) administering inciting event means to a target skin location on the subject to induce an inciting event, and (iii) administering...

Method and composition for altering a b cell mediated pathology
10/30/14 - 20140322160 - The present invention provides compositions for altering a B cell mediated pathology in a patient. The compositions may comprise at least one and/or two chimeric proteins. Each chimeric protein comprises at least a portion of either the VH or VL region of an immunoglobulin module from particular B cells from...

Dual delivery system for heterologous antigens
10/23/14 - 20140314708 - Provided herein are recombinant Listeria strains expressing a tumor-specific antigenic polypeptide and, optionally, an angiogenic polypeptide wherein a nucleic acid molecule encoding at least one of the polypeptides is operably integrated into the Listeria genome in an open reading frame with a nucleic acid sequence encoding a PEST-containing polypeptide, methods...

Combination therapies for treating type 1 diabetes
10/09/14 - 20140301973 - In accordance with the subject invention, combination therapies can be used to modulate a patient's immune response in order to prevent, delay and/or reverse type 1 diabetes....

Novel use of ganodermic acids for treating cancer
10/02/14 - 20140294753 - Novel Uses of a small molecule, ganodermic acid S (GMAS), are disclosed herein. The GMAS is useful as a lead compound for manufacturing a medicament or a pharmaceutical composition for treating cancer, including metastatic or drug-resistant cancer, in a patient....

Use of tumor fas expression to determine response to anti-cancer therapy
10/02/14 - 20140294754 - The invention provides methods for using expression levels of Fas to select individuals or subpopulation of individuals who can benefit from an anti-cancer therapy and for assessing whether an individual suspected of having or developing cancerous tumors will beneficially respond to an anticancer therapy. The invention additionally provides methods of...

Materials and methods relating to stem cell mobilization by multi-pegylated granulocyte colony stimulating factor
10/02/14 - 20140294755 - The present invention relates to the use of multi-PEGylated granulocyte colony stimulating factor (G-CSF) preparations to mobilize hematopoietic stem cells....

Long-term storage of non-glycosylated recombinant human g-csf
10/02/14 - 20140294756 - The present invention provides a method for stable long-term storage of non-glycosylated recombinant human G-CSF, wherein an aqueous acetate or glutamate buffered G-CSF composition containing the non-glycosylated recombinant human G-CSF and sorbital is cooled to a temperature of −15° C. or below to obtain a frozen G-CSF composition, which frozen...

Stabilisation of polypeptides
10/02/14 - 20140294757 - A method for preserving a polypeptide comprising: (a) providing an aqueous solution of (i) the polypeptide, (ii) one or more sugars, and (iii) a compound of formula (I) or a physiologically acceptable salt or ester thereof and/or a compound of formula (II) or a physiologically acceptable salt or ester thereof;...

Methods and compositions for promoting organ development
09/25/14 - 20140286895 - Compositions and methods are provided for promoting organ development in warm blooded animals, and in particular in certain aspects a premature infant or fetus. Compositions and methods are also provided for the administration of at least one colony stimulating factor-1 protein (CSF-1), precursor, variant, analogue, derivative thereof, or combinations thereof,...

Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia in pediatric patients
09/18/14 - 20140271538 - Disclosed are methods and compositions for treating, preventing and ameliorating conditions and diseases characterized by a lowered white blood cell count, including neutropenia, in human patients that are less than 18 years old. The methods and compositions described herein include a fusion polypeptide comprising human serum albumin protein (“HSA”) and...

Methods of treating cognitive impairment
09/11/14 - 20140255337 - The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3...

Edar ligand derived peptides and use thereof
09/11/14 - 20140255338 - The present invention relates to novel peptides derived from an EDAR (EDAR receptor) ligand which belongs to TNF (tumor necrosis factor)-α family and to uses of the same. The present peptides of EDA3 derived from EDA and EDphD1 derived from EDAR ligand possess identical or similar activities to naturally occurring...

Use of g-csf dimer in preparation of medicament for treatment of neurodegenerative diseases
09/04/14 - 20140248234 - The invention discloses the use of the G-CSF dimer in the preparation of a medicament for the treatment of neurodegenerative diseases. Use of the G-CSF dimer of the present invention can significantly increase the number of dopaminergic neuron in the substantia nigra in PD model animals and enhance the function...

Compositions and methods comprising bmp-7
08/14/14 - 20140227219 - In an aspect, the invention relates to compositions comprising BMP-7 and methods of using disclosed compositions. In an aspect, the invention relates to compositions for and methods of treating atherosclerosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended...

Method for treating chemotherpay-induced male infertility
08/14/14 - 20140227220 - A method of ameliorating, inhibiting, preventing, or reducing male infertility in a subject undergoing or in need of chemotherapy by administering to the subject a granulocyte colony-stimulating factor in a protective amount, prior to, during or after administration of one or more chemotherapeutic agents to the subject....

Methods of treatment using stem cell mobilizers
08/07/14 - 20140219952 - The present invention relates to the field of stem cells. In one aspect, the present invention provides methods of treating a subject with acute liver injury comprising administering to the subject a therapeutically effective amount of at least one stem cell mobilizer. In particular embodiments, the subject is treated with...

Adhesive cell tissue gels
08/07/14 - 20140219953 - Described herein is a cell tissue gel cross-linked with a cross-linking agent, and a quenching agent bound to a reactive group of the cross-linking agent....

Dry powder formulations of organic macromolecules
08/07/14 - 20140219954 - The present invention relates to methods for making a stabilized powder formulation for inhalation comprising a macromolecule in lyophilized form, a crystalline carrier material, and magnesium stearate....

Listeria-based adjuvants
07/17/14 - 20140199258 - This invention provides methods and compositions for using Listeria monocytogenes as an adjuvant for enhancing immune responses in a subject....

Derivatives of recombinant proteins, homo-multimers of granulocyte colony-stimulating factor and method of preparation thereof
07/10/14 - 20140193357 - The invention relates to derivatives of recombinant proteins, comprising homo-multimers of genetically fused recombinant biologically active protein monomer units, connected via selected peptide linker moiety; and the method of preparation thereof. Derivative of recombinant protein is preferably dimer of human granulocyte colony-stimulating factor, characterised by increased circulation time in vivo....

Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response
07/03/14 - 20140186292 - Methods are disclosed for producing defective ribosomal products (DRiPs) in blebs (DRibbles) by contacting cells with a proteasome inhibitor, and in some examples also an autophagy inducer, thereby producing treated cells. DRibbles can be used to load antigen presenting cells (APCs), thereby allowing the APCs to present the DRiPs and...

Variants of the tnf superfamily and uses thereof
06/26/14 - 20140178329 - Described are novel variants of APRIL that modulate signaling via receptor-specific agonist activity, and nucleic acids encoding these variant proteins. Further described is the use of these novel proteins in the treatment of APRIL-associated disorders, in particular, pathologies of the immune system and oncological disorders....

Regulation of energy metabolism and obesity by modulating b cell activating factor (baff, blys) or baff signaling
06/19/14 - 20140170107 - Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells,...

Derivatisation of granulocyte colony-stimulating factor
06/12/14 - 20140161765 - The present invention relates to a compound which is a polysaccharide derivative of GCSF, or of a GCSF like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the...

Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
06/05/14 - 20140154205 - A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of Erythropoietin and about 100-300 mg per cm2 wound tissue of...

Smac mimetic dimers and trimers useful as anti-cancer agents
05/08/14 - 20140127155 - The invention provides small molecule mimics of the Smac peptide that are dimer-like or trimer-like compounds having two or three amide-containing domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including...

Prostate cancer vaccine
04/17/14 - 20140105853 - Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer. Also disclosed are methods for inducing immune reaction to androgen receptor or treating prostate cancer in a mammal, using the vaccines and pharmaceutical...

Metal alloys for medical devices
04/10/14 - 20140099279 - A medical device that is at least partially formed of a novel metal alloy, which novel metal alloy improves the physical properties of the medical device....

Suppression of bone loss by introducing foxp3+ cd8 t-cells (tcreg)
04/03/14 - 20140093475 - Systems and methods for inhibiting bone loss using FoxP3+ CD8 T-cells (TcREG). Osteoclasts are induced to produce FoxP3+ CD8 T-cells (TcREG) either in vivo or ex vivo. The FoxP3+ CD8 T-cells (TcREG) are provided to the patient to subsequently regulate osteoclast function, thereby establishing a bi-directional regulatory loop between osteoclasts...

Systems, compositions and methods for the treatment of alopecia
03/27/14 - 20140086867 - A method of inducing or promoting hair growth on the scalp of a subject, comprising the steps of (i) providing an ECM composition including at least one ECM material, (ii) administering inciting event means to a target location on the scalp of the subject to induce an inciting event at...

Cellular therapeutic approaches to traumatic brain and spinal cord injury
02/27/14 - 20140056842 - The described invention provides cellular therapeutic approaches for treating a vascular insufficiency following a traumatic injury to head or spine that results in an injury to brain, spinal cord, or both by administering a therapeutic amount of an isolated, nonexpanded population of autologous mononuclear cells comprising a subpopulation of CD34+...

Tnfsf single chain molecules
02/27/14 - 20140056843 - The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications....

Conjugates of a gm-csf moiety and a polymer
02/13/14 - 20140044672 - Conjugates of a GM-CSF moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions comprising conjugates to a patient....

P2x7: inhibition of epithelial cancers and papillomas
02/06/14 - 20140037576 - The present invention demonstrates that P2X7 receptor induced apoptosis may be specific for cancerous cells. Treatment with the P2X7 ligand BzATP, increased cellular apoptosis with no associated inflammatory changes or abnormal skin or systemic effects. In mice treated with DMBA/TPA, BzATP decreased papilloma skin formation. BzATP also induced involution of...

Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
02/06/14 - 20140037577 - The present invention includes methods and compositions for the treatment and prevention of protozoal parasitic infections utilizing Diindolylmethane-related indoles. Additive and synergistic interaction of Diindolylmethane-related indoles with other known anti-parasitic and pro-apoptotic agents is believed to permit more effective therapy and prevention of protozoal parasitic infections. The methods and compositions...

Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof
01/30/14 - 20140030211 - The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for providing improved bone marrow transplantation and in the treatment of other conditions wherein bone marrow depletion or suppression is involved....

Compositions, methods and devices for activating an immune response
01/30/14 - 20140030212 - The invention provides a method, system, process, vaccine, or device for activating an immune response against a tumor. In particular, in one embodiment, the invention for activating an immune response in situ against a tumor comprises introducing one or more delivery devices having a morphology that prioritizes one or more...

Process for purification of recombinant granulocyte colony stimulating factor (rhu gcsf)
01/30/14 - 20140030213 - The present invention relates to methods for purification of recombinant human granulocyte colony stimulating factor (rHu GCSF). The present invention particularly relates to methods for purification of rHu GCSF involving techniques such as aqueous two phase extraction and multimodal chromatographic purification to obtain highly purified rHu GCSF. The present invention...

Liquid formulation of g-csf
01/30/14 - 20140030214 - Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits....

Macrophage activating factor for pharmaceutical compositions
01/30/14 - 20140030215 - Pharmaceutical compositions including macrophage activating factor (MAF) and method of producing same, particularly to MAF compositions essentially devoid of glycosidase enzymes. The compositions of the present invention and pharmaceutical compositions including same are particularly suitable for intravenous administration....

Advertise on FreshPatents.com - Rates & Info

###

FreshPatents.com Support - Terms & Conditions